

Diabetes Management Committee meeting

Date: 28/04/2017

Location: London

Minutes: Final

Committee members present:	
Steve Pilling (Chair) (SP)	Section 1- 7
Jo Josh (JJ)	Section 1- 7
Grace Marsden (GM)	Section 1- 7
Simon Corbett (Condition Specific) (SC)	Section 1- 7
David Liggins (Condition Specific) (DL)	Section 1- 7
Jean MacLeod (Condition Specific) (JM)	Section 1- 7
Dianna Oxley (Condition Specific) (DO)	Section 1- 7
Krishnarajah Nirantharakumar (Topic Expert) (KN)	Section 1- 7

In attendance:		
Omnia Abdulrazeg (OA)	Technical Analyst - NICE	Section 1- 7
Jamie Elvide (JE)	Health Economist – NICE	Section 1- 7
Andy Hutchinson (AH)	Technical Adviser - NICE	Section 1- 7
Yolanda Martinez (YM)	Technical Analyst - NICE	Section 1- 7
Adam O’Keefe (AO)	Project Manager - NICE	Section 1- 7
Joshua Pink (JP)	Technical Adviser - NICE	Section 1- 7
Nick Staples (NS)	Guideline Commissioning Manager - NICE	Section 1- 7
Lee Walker (LW)	Resource Impact Lead – NICE	Section 1- 7

Apologies:
Parveen Ali (Core Member)
Jim Gray (Core Member)
Julian Treadwell (Core Member)
Ivan Benett (Condition Specific)
Andrew Barron (Topic Expert)

Diabetes Management: Minutes

1. Welcome

The Chair welcomed the Committee members and attendees to the first meeting on Diabetes Management.

The meeting was opened to the public. The committee and NICE team introduced themselves. The Chair informed the Committee that apologies had been received which are noted above.

The Chair welcomed the members of the public to the meeting. The members of the public had been briefed already, both verbally and in writing by the NICE team, and the Chair reminded them of the protocol for members of the public, whose role is to observe (they should not speak or ask questions). No filming or recording of the meeting is permitted. The Chair reminded all present that the Committee is independent and advisory, that its decisions and recommendations to NICE do not represent final NICE guidance, and that they may be changed as a result of public consultation.

The Chair outlined the objectives of the meeting:

- To consider the clinical evidence for the topic
- To consider the health economic model

The Chair advised all present that recommendations would not be drafted at this meeting.

Committee members had previously been asked to complete a Declarations of Interest form. The Chair asked the committee members and the NICE team to declare if they have any additional conflicts of interest, or conflicts relating to today's meeting agenda. The following new interest was declared:

Name	Job title, organisation	Declarations of Interest, date declared	Classification of interest	Decision taken
Topic expert members				
Dianna Oxley	Lay member	Voluntary patient rep for the British Heart Foundation Declared – 28/04/2017	Personal Non-financial Non-specific	Declare and Participate

The Chair and a senior member of the Developer's team noted that the interests declared did not prevent attendees from fully participating in the meeting.

2. Topic Overview: Diabetes Management

The Chair introduced OA, Technical Analyst, who presented an introduction to the topic for the benefit of the attendees and observers. OA then invited the Lay

Diabetes Management: Minutes

members to talk about their experiences in the area to be discussed. The Chair gave the committee chance to ask questions of the topic experts and lay members.
3. Review question 2a: In adults with Type 2 diabetes, what is the clinical effectiveness of GLP1 mimetics on cardiovascular outcomes?
OA recapped the search protocol and presented the clinical evidence supporting Review Question 2a for the committee's consideration. The Committee discussed the evidence and provided clarification on a number of queries from the NICE team.
4. Discussion of health economics JE presented the committee with available health economic evidence supporting Review Question 2b and explained that there were no relevant health economic data identified for Review Question 2a. The Committee then discussed the economic modelling considerations relating to the review questions and whether the existing model needed to be adapted to enable the review questions to be answered. JE will carry on with the analysis and results will be presented at a future meeting. Health economic evidence for Review Question 1 will be presented at the next meeting.
5. Review questions 2b: In adults with Type 2 diabetes, what are the differences between a). The assumptions used in the HE model that informed NG28 and b). The empirical evidence from RCTs?
Discussed under items 4 above.
6. Review question 1: In adults with Type 2 diabetes, what is the clinical effectiveness of SGLT-2 inhibitors on cardiovascular outcomes?
JP provided a brief introduction to the topic being discussed. YM then sought clarification from the committee on a number of points to inform the data analysis.
7. Next steps and AOB
AO advised the Committee on the next phase key dates for the update. The Chair summarised the day and thanked the Committee for their contribution to the meeting.

Date of next meeting: 17 July 2017

Location of next meeting: NICE London Office